Compare Bristol-Myers Squibb Co (BMY) vs Salesforce Inc (CRM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Salesforce Inc — how do they compare? Bristol-Myers Squibb Co trades at $63.57 (market cap $129.94B), while Salesforce Inc trades at $195.77 (market cap $161.73B). The key difference: Salesforce Inc is the larger of the two by market cap, and Bristol-Myers Squibb Co pays the higher dividend (3.96%). Which is the better fit depends on your goals.
| BMY | CRM | |
|---|---|---|
Market Cap | $129.94B | $161.73B |
Sector | Health | Technology |
52-Week High | $65.89 | $266.23 |
52-Week Low | $42.60 | $150.12 |
Enterprise Value | $163.92B | $191.77B |
Dividend Yield | 3.96% | 0.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $64.84, up 0.19% today, with a bullish technical signal from moving averages and strong fundamental health evidenced by a 14.01 P/E ratio and 18.87% net income margin. Recent earnings beats and a $2.3 billion manufacturing investment in Houston highlight operational strength, while analyst consensus is mixed with a $68.56 price target.
The outlook is positive due to earnings momentum and strategic investments, but risks include patent expirations and high debt levels. Wall Street sentiment is cautiously optimistic, with institutional buying supporting the stock's potential for moderate upside from current levels.
Salesforce (CRM) trades at $197.51, up 2.47% with strong technical momentum as the stock approaches resistance at $200. The company demonstrates robust fundamentals with consistent earnings beats, posting Q1 2026 EPS of $3.88 versus $3.13 expected, and maintains impressive profitability with 77.64% gross margins. Revenue growth accelerated to $37.9B in 2025 with net income reaching $6.2B, while analyst sentiment remains overwhelmingly positive with 76% buy ratings.
Outlook remains favorable with AI-driven growth catalysts and a $230.61 consensus price target offering 17% upside potential. Key risks include competitive pressures in the SaaS sector and market volatility from AI disruption concerns. The stock presents a compelling opportunity given its Rule of 44 performance metrics and strong cash flow generation of $13.1B from operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Salesforce Inc
Salesforce Inc provides enterprise cloud computing solutions. The company offers customer relationship management technology that brings companies and customers together. Its Customer 360 platform helps the group to deliver a single source of truth, connecting customer data across systems, apps, and devices to help companies sell, service, market, and conduct commerce. It also offers Service Cloud for customer support, Marketing Cloud for digital marketing campaigns, Commerce Cloud as an e-commerce engine, the Salesforce Platform, which allows enterprises to build applications, and other solutions, such as MuleSoft for data integration.
Read more on CRM →
